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Abstract: Hypereosinophilic syndrome (HES) encompasses numerous diverse conditions 
resulting in peripheral hypereosinophilia that cannot be explained by hypersensitivity, infection, 
or atopy and that is not associated with known systemic diseases with specific organ involvement. 
HES is often attributed to neoplastic or reactive causes, such as chronic eosinophilic leukemia, 
although a majority of cases remains unexplained and are considered idiopathic. Here, we 
review the current diagnosis and management of HES and present a unique case of profound 
hypereosinophilia associated with warm autoimmune hemolytic anemia requiring intensive 
management. This case clearly illustrates the limitations of current knowledge with respect 
to hypereosinophilia syndrome as well as the challenges associated with its classification and 
management.
Keywords: hypereosinophilia, eosinophils, myeloproliferative disorder, autoimmune hemolytic 
anemia, idiopathic autoimmune hemolytic anemia, leukemia
Introduction
Peripheral hypereosinophilia is most commonly associated with allergic causes, includ-
ing drug hypersensitivity, parasitic infection, or atopic disease. Hypereosinophilic 
syndrome (HES) encompasses a group of disorders that cannot be explained by these 
common causes.1 True HES is rare, with an estimated incidence of 0.36 cases per 
100,000 person-years and affects predominantly men between the ages of 20 and 
50 years.2 Following exclusion of common known causes of hypereosinophilia, HES 
is diagnosed by confirming the presence of $1.5×109 cells/L on two occasions sepa-
rated by at least 1 month and by determining the evidence of organ involvement.3 
HES can be subclassified broadly as 1) a primary disorder of myeloid cells resulting 
in monoclonal proliferation (eg, neoplasia), 2) a secondary expansion of polyclonal, 
reactive eosinophils (eg, cytokine driven proliferation), or 3) an otherwise unexplained 
increase in eosinophils (idiopathic HES).4
Warm autoimmune hemolytic anemia (WAIHA) is a potentially life-threatening 
condition characterized by the presence of intravascular hemolysis, spherocytes 
in peripheral smear, and anti-red blood cell (RBC) antibodies, known as warm 
agglutinins that bind to RBC antigens at room temperature.5 Common etiologies 
of WAIHA include drug reaction, viral infection, autoimmune or connective tissue 
disease, and hematological malignancy, particularly chronic lymphocytic leukemia.6 
Despite potential underlying lymphoproliferative and immune dysregulation, to our 
knowledge, there have been only two reported cases of idiopathic HES associated 
with WAIHA.7,8 Here, we present the diagnosis and management of an unusual case 
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of profound hypereosinophilia (49.9×109 cells/L) associated 
with WAIHA, but without identifiable neoplastic etiology.
Case report
A 25-year-old male with a past medical history, significant 
only for frequent use of ibuprofen for musculoskeletal pain, 
presented to the emergency department with acute onset fever 
and malaise. On arrival, the patient was quickly found to be 
hypotensive and tachypneic, with scleral icterus evident on 
physical exam. Otherwise, no cardiac, pulmonary, gastroin-
testinal, neurological, or dermatological irregularities were 
reported. Preliminary laboratory evaluation demonstrated 
profound anemia (hemoglobin: 5.4, hematocrit: 13.0), and 
the patient was admitted to the intensive care unit for further 
management, with a working diagnosis of systemic inflam-
matory response syndrome with severe anemia.
A direct antiglobulin test was positive for anti-erythrocyte 
IgG, supporting the diagnosis of WAIHA.9 Peripheral blood 
smear showed significant eosinophilia (49.9×109 cells/L) with 
no blasts (Figure 1). A subsequent bone marrow biopsy was 
negative for the presence of a leukemic or lymphoprolifera-
tive process and found no evidence of PDGFR-A mutation 
or BCR/ABL translocation (Figure 2). Flow cytometry was 
performed and similarly showed no evidence of a leukemic 
or lymphoproliferative process. Further workup with transt-
horacic echocardiography and CT scan of the neck and torso 
found no neoplastic disease. A survey for infectious etiologies 
associated with eosinophilia revealed a negative Entamoeba 
histolytica, Toxocara, Trichinella, Strongyloides stercoralis, 
Hepatitis B and C, and HIV serologies. A QuantiFERON 
Gold® (Cellestis Ltd, Carnegie, VIC, Australia) as well as 
blood cultures, urine cultures, stool cultures, stool white blood 
cell count, and stool ova and parasites were unremarkable. To 
rule out other causes of eosinophilia, a cortisol stimulation test 
(adrenal insufficiency), anti-neutrophil cytoplasmic antibodies 
(eosinophilic granulomatosis with polyangiitis), and vitamin 
B
12
 (myeloproliferative disease) were examined, all of which 
were found to be within normal limits. Of note, an abdominal 
ultrasound revealed mild hepatosplenomegaly.
On admission to the intensive care unit, the patient 
received transfusion of 4 units of packed RBCs and was 
treated with high-dose intravenous glucocorticoids (methyl-
prednisone 120 mg intravenous every 6 hours for 1 day, fol-
lowed by prednisone 60 mg oral administration daily). His 
hemoglobin and eosinophil count stabilized (hemoglobin: 
9.2, hematocrit: 26.5, eosinophil count: 0.8×109 cells/L) 
and the patient was discharged in 5 days, with a prednisone 
taper to complete his glucocorticoid therapy, and instructed 
to avoid nonsteroidal anti-inflammatory drugs (NSAIDs) as 
possible precipitants of hemolytic anemia. The treatment plan 
for this patient consisted of short-interval follow-up, with 
hematology and oncology to reassess blood count. The patient 
was instructed to return to the hospital for any concerning 
symptoms such as fatigue, fevers, chills, and night sweats. 
Unfortunately, the patient was lost to follow-up.
Discussion
A general diagnostic approach for a patient with hypereosino-
philia is displayed in Figure 3. Following exclusion of infec-
tious and atopic etiologies as causes of hypereosinophilia, the 
differential diagnosis in our patient consisted of adverse drug 
hypersensitivity to ibuprofen, chronic eosinophilic leukemia 
with AIHA, or idiopathic HES with AIHA.
Despite being considered as generally benign agents, 
NSAIDs such as ibuprofen are known precipitants of adverse 
drug reactions associated with hypereosinophilia. Drug reaction Figure 1 examination of peripheral blood smear.
Figure 2 Bone marrow biopsy.
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Considerations in idiopathic Hes with WaIHa
with eosinophilia and systemic symptoms (DRESS) is a rare, 
potentially life-threatening condition that infrequently may 
result from use of NSAIDs and, more rarely, may be associated 
with autoimmune phenomena, including hemolytic anemia.10,11 
Alternatively, simultaneous drug-induced immune hemolytic 
anemia resulting from NSAID use may explain this patient’s 
presentation.12 Although the likelihood of an adverse immune 
reaction to ibuprofen may have been elucidated through an 
elution test, such a test was not available at the time of this 
patient’s presentation and may be of questionable value.13 
However, DRESS or other drug hypersensitivities would not 
be expected to result in an eosinophil count of nearly 50×109 
cells/L, and no rash was present in this patient, suggesting an 
underlying neoplastic process may be more likely.14
Neoplastic etiologies of hypereosinophilia syn-
drome may be myeloproliferative or lymphoproliferative. 
Lymphoproliferative syndromes including B-cell acute 
lymphoblastic leukemia, Hodgkin lymphoma, adult T-cell 
 leukemia/lymphoma, and cutaneous T-cell lymphoma (Sézary 
syndrome) may produce a reactive eosinophilia in response to 
dysregulated cytokine secretion, particularly IL-5.15 However, 
blood smear and bone marrow biopsy demonstrated no evi-
dence of underlying lymphoproliferative disease. Therefore, 
this patient’s hypereosinophilia most likely had an underlying 
myeloproliferative origin.
Myeloproliferative etiologies of hypereosinophilia 
include primary HES, acute eosinophilic leukemia, chronic 
eosinophilic leukemia, and chronic myeloid leukemia. In 
this patient, the only abnormality observed was the presence 
of increased mature eosinophils on peripheral blood smear, 
making chronic myeloid leukemia and acute eosinophilic 
leukemia unlikely. While PDGFR-A, the most common 
mutation associated with myeloproliferative HES, was not 
found in our workup, other underlying mutations, such as in 
PDGFR-B or FGFR1, may have been present and resulted in 
HES. Interestingly, one case of chronic eosinophilic leukemia 
associated with warm hemolytic anemia has previously been 
reported in the literature.16
Although a presumptive diagnosis of myeloproliferative 
hypereosinophilia syndrome could be made, like the major-
ity of cases of HES, a definitive diagnosis was not possible. 
Nevertheless, our case effectively demonstrates the diagnostic 
process to be followed in patients presenting with HES, as 
well as various treatment considerations. Fortunately, our 
patient did not suffer significant complications from severe 
hypereosinophilia that may include cutaneous manifestations, 
pulmonary symptoms, cardiac symptoms (eg, myocarditis), 
and neurological abnormalities, although the prognosis 
remains guarded as there is a known possibility for such 
patients to develop acute myeloid leukemia, sometimes years 
later.17 In this particular case, the use of high-dose glucocor-
ticoids alone was sufficient to elicit response, and, in com-
bination with transfusion, effectively suppress symptomatic 
hemolytic anemia. In other cases of HES associated with 
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Figure 3 a general diagnostic approach for patients with hypereosinophilia.
Abbreviations: GI, gastrointestinal; Hess, hypereosinophilic syndromes; CeL, chronic eosinophilic leukemia.
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mutations in PDGFR-A or -B, the tyrosine kinase imatinib 
may be associated with an effective clinical response.18
Conclusion
Hypereosinophilia syndrome represents a poorly character-
ized cohort of heterogeneous diseases that may have incred-
ibly diverse presentations. Despite advances in molecular 
diagnostics and cancer research, the majority of cases of 
HES lack definitive diagnosis. Here, we have presented a rare 
case of HES associated with AIHA and reviewed the relevant 
diagnostic and therapeutic considerations. Further work is 
needed to better characterize the underlying molecular and 
genetic factors underlying the development of HES, create 
improved diagnostic tools, and improve treatment options 
for affected patients.
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